SINDHU R. JOHNSON, MD, PHD
DIRECTOR
Toronto Scleroderma Program
Clinical Epidemiology & Health Care Research Program, Dalla Lana School of Public Health
CLINICIAN-SCIENTIST
University Health Network & Sinai Health Systems
PROFESSOR
Medicine & Institute of Health Policy, Management and Evaluation, University of Toronto
Toronto, Canada
Dr. Sindhu Johnson is a Professor of Medicine at the University of Toronto and Director of the Toronto Scleroderma Program. She is also Director of the Clinical Epidemiology Program at the Dalla Lana School of Public Health, University of Toronto, Canada.
Dr. Johnson has published over 260 articles in peer reviewed journals, secured $6 million dollars in salary support and operating grant funding, published 5 book chapters, and invited to 4 Editorial Boards. She has supervised 20 international clinical research fellows and graduate students, most of whom have established Scleroderma Programs or have academic appointments in their home countries.
Dr. Johnson has led collaborations between the American College of Rheumatology and the European League Against Rheumatism for the development of classification criteria for systemic sclerosis and systemic lupus erythematosus. She has been a site investigator for the first two FDA approved medications (nintedinib, tocilizumab) for scleroderma associated interstitial lung disease (ILD). She is the Principal Investigator for the American College of Rheumatology, American College of Chest Physicians guidelines for the screening, monitoring and treatment of ILD in the systemic autoimmune rheumatic diseases.